(Q37104856)

18 August 2017

1 reference

title

Aliskiren-hydrochlorothiazide combination for the treatment of hypertension (English)

1 reference

18 August 2017

main subject

arterial hypertension

0 references

author name string

Steven G Chrysant

series ordinal

1

1 reference

18 August 2017

publication date

1 March 2008

1 reference

Expert Review of Cardiovascular Therapy

18 August 2017

published in

1 reference

18 August 2017

volume

6

1 reference

18 August 2017

issue

3

1 reference

18 August 2017

page(s)

305-314

1 reference

Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004.

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Renin inhibition with aliskiren: where are we now, and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Direct renin inhibition with aliskiren in hypertension and target organ damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Structure-based design of aliskiren, a novel orally effective renin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Renin, prorenin and the putative (pro)renin receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Direct inhibition of renin as a cardiovascular pharmacotherapy: focus on aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren: a review of its use in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Direct Renin inhibition with aliskiren in obese patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Species specificity of renin kinetics in transgenic rats harboring the human renin and angiotensinogen genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Pathophysiology of target-organ disease: does angiotensin II remain the key?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

Dual inhibition of the renin system by aliskiren and valsartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.6.3.305

21 January 2018

Identifiers

DOI

10.1586/14779072.6.3.305

1 reference

18 August 2017

1 reference